The Burrill Report

The Burrill Report (December 24, 2012): Removing IP Barriers to Innovation (.MP3,13.16 Mb)

As drug developers look to changing models of collaboration to address flagging R&D productivity, intellectual property may pose a barrier to realizing the full benefits of the new approaches. Garret FitzGerald, director of The Institute of Translational Medicine and Therapeutics at the University of Pennsylvania’s Perelman School of Medicine, argues current management of intellectual property constrains interaction between industry and academia. We spoke to FitzGerald about how drug development is changing, lessons to be learned from other industries, and why the industry’s approach to intellectual property needs to change.

December 20, 2012
http://www.burrillreport.com/article-removing_ip_barriers_to_innovation.html